BLFS Stock Analysis: BioLife Solutions | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.889m USD | 12M Return: 45.6% | US09062W2044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.2M
Qual. Beats: 0
Rev. Trend: -42.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioLife Solutions, Inc. (BLFS) is a U.S.-based supplier of bioproduction tools and services for the cell and gene therapy (CGT) industry, with operations spanning North America, Europe, the Middle East, and Africa. The companys portfolio spans the workflow, including biopreservation media (HypoThermosol FRS, CryoStor), human platelet lysates for cell expansion, closed-system vials (CellSeal), cryo-compatible containers (CryoCase), automated thawing systems (ThawSTAR), and cloud-connected passive shipping containers (evo). Products serve both research and commercial-scale manufacturing of biologic-based therapies.
The company sells directly and through third-party distributors, serving a sector in which preserving cell viability and maintaining cold-chain integrity are critical because CGT products are inherently temperature-sensitive and often patient-specific, leaving little tolerance for losses during storage, transport, or thawing.
Founded in 1987 and headquartered in Bothell, Washington, BLFS is classified within the Health Care Supplies sub-industry and operates as a small-cap company with a market capitalization of approximately $1.2 billion USD.
- Cell and gene therapy approvals boost biopreservation media demand
- Acquisition integration costs pressure near-term operating margins
- Competition intensifies from Thermo Fisher in bioproduction tools
| Net Income: 50.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -3.16 > 1.0 |
| NWC/Revenue: 117.9% < 20% (prev 126.9%; Δ -9.01% < -1%) |
| CFO/TA 0.04 > 3% & CFO 16.9m > Net Income 50.4m |
| Net Debt (-66.7m) to EBITDA (9.78m): -6.82 < 3 |
| Current Ratio: 9.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.3m) vs 12m ago 3.13% < -2% |
| Gross Margin: 64.48% > 18% (prev 81.42%; Δ -16.94% > 0.5%) |
| Asset Turnover: 24.63% > 50% (prev 19.76%; Δ 4.88% > 0%) |
| Interest Coverage Ratio: 2.29 > 6 (EBIT TTM 6.21m / Interest Expense TTM 2.71m) |
| A: 0.27 (Total Current Assets 135.2m - Total Current Liabilities 13.9m) / Total Assets 447.5m |
| B: -0.66 (Retained Earnings -293.4m / Total Assets 447.5m) |
| C: 0.01 (EBIT TTM 6.21m / Avg Total Assets 417.4m) |
| D: 15.28 (Book Value of Equity 420.0m / Total Liabilities 27.5m) |
| Altman-Z'' = 15.78 = AAA |
| DSRI: 0.79 (Receivables 10.7m/10.1m, Revenue 102.8m/76.5m) |
| GMI: 1.26 (GM 81.42% / 64.48%) |
| AQI: 1.02 (AQ_t 0.64 / AQ_t-1 0.63) |
| SGI: 1.34 (Revenue 102.8m / 76.5m) |
| TATA: 0.08 (NI 50.4m - CFO 16.9m) / TA 447.5m) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of October 07, 2026, the stock is trading at USD 38.61 with a total of 4,446,000 shares traded. Over the past week, the price has changed by -1.38%, over one month by +9.13%, over three months by +38.93% and over the past year by +45.59%.
Current recommended Stop Loss: 37.20 (which is 3.7% or 1.3 ATR below the current price).
BioLife Solutions has received a consensus analysts rating of 3.22. Therefore, it is recommended to hold BLFS.
- StrongBuy: 1
- Buy: 0
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.3 | -19% |
P/E Trailing = 39.0
P/E Forward = 238.0952
P/S = 17.7052
P/B = 4.3926
P/EG = 65.3833
Revenue TTM = 102.8m USD
EBIT TTM = 6.21m USD
EBITDA TTM = 9.78m USD
Long Term Debt = 13.1m USD (estimated: total debt 15.7m - short term 2.59m)
Short Term Debt = 2.59m USD (from shortTermDebt, last quarter)
Debt = 15.7m USD (from shortLongTermDebtTotal, last quarter) (leases 15.7m already included)
Net Debt = -66.7m USD (calculated: Debt 15.7m - CCE 82.4m)
Enterprise Value = 1.82b USD (1.89b + Debt 15.7m - CCE 82.4m)
Interest Coverage Ratio = 2.29 (Ebit TTM 6.21m / Interest Expense TTM 2.71m)
EV/FCF = -1000.0x (Enterprise Value 1.82b / FCF TTM -904k)
FCF Yield = -0.05% (FCF TTM -904k / Enterprise Value 1.82b)
FCF Margin = -0.88% (FCF TTM -904k / Revenue TTM 102.8m)
Net Margin = 49.06% (Net Income TTM 50.4m / Revenue TTM 102.8m)
Gross Margin = 64.48% ((Revenue TTM 102.8m - Cost of Revenue TTM 36.5m) / Revenue TTM)
Gross Margin QoQ = 64.24% (prev 63.31%)
Tobins Q-Ratio = 4.07 (Enterprise Value 1.82b / Total Assets 447.5m)
Interest Expense / Debt = 17.19% (Interest Expense 2.71m / Debt 15.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 4.90m (EBIT 6.21m * (1 - 21.00%))
Current Ratio = 9.69 (Total Current Assets 135.2m / Total Current Liabilities 13.9m)
Debt / Equity = 0.04 (Debt 15.7m / totalStockholderEquity, last quarter 420.0m)
Debt / EBITDA = -6.82 (Net Debt -66.7m / EBITDA 9.78m)
Debt / FCF = 73.76 (negative FCF - burning cash) (Net Debt -66.7m / FCF TTM -904k)
Total Stockholder Equity = 379.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.09% (Net Income 50.4m / Total Assets 447.5m)
RoE = 13.29% (Net Income TTM 50.4m / Total Stockholder Equity 379.5m)
RoCE = 1.58% (EBIT 6.21m / Capital Employed (Equity 379.5m + L.T.Debt 13.1m))
RoIC = 1.14% (NOPAT 4.90m / Invested Capital 431.0m)
WACC = 9.99% (E(1.89b)/V(1.90b) * Re(9.96%) + D(15.7m)/V(1.90b) * Rd(17.19%) * (1-Tc(0.21)))
Discount Rate = 9.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.10 | Cagr: 3.69%
[DCF] Fair Price = unknown (Cash Flow -904k)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.39 | # QB: 0
Revenue Correlation: -42.03 | Revenue CAGR: -9.84% | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.07 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.25 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+91.9% | GrowthRev=+19.8%
EPS next Year (2027-12-31): EPS=0.33 | Chg30d=+13.79% | Revisions=+25% | GrowthEPS=+32.0% | GrowthRev=+17.0%